nodes	percent_of_prediction	percent_of_DWPC	metapath
Tolmetin—PTGS2—amyotrophic lateral sclerosis	0.732	1	CbGaD
Tolmetin—TDO2—Monoamine Transport—SLC6A1—amyotrophic lateral sclerosis	0.00701	0.0529	CbGpPWpGaD
Tolmetin—Glossitis—Riluzole—amyotrophic lateral sclerosis	0.006	0.0612	CcSEcCtD
Tolmetin—CXCL8—ATF4 activates genes—EXOSC9—amyotrophic lateral sclerosis	0.00561	0.0423	CbGpPWpGaD
Tolmetin—CXCL8—PERK regulates gene expression—EXOSC9—amyotrophic lateral sclerosis	0.00512	0.0387	CbGpPWpGaD
Tolmetin—CXCL8—Senescence and Autophagy in Cancer—GABARAPL2—amyotrophic lateral sclerosis	0.00497	0.0375	CbGpPWpGaD
Tolmetin—Lymphadenopathy—Riluzole—amyotrophic lateral sclerosis	0.00471	0.048	CcSEcCtD
Tolmetin—Vascular purpura—Riluzole—amyotrophic lateral sclerosis	0.00449	0.0458	CcSEcCtD
Tolmetin—Cardiac failure congestive—Riluzole—amyotrophic lateral sclerosis	0.00443	0.0451	CcSEcCtD
Tolmetin—Purpura—Riluzole—amyotrophic lateral sclerosis	0.00417	0.0425	CcSEcCtD
Tolmetin—Anaphylactoid reaction—Riluzole—amyotrophic lateral sclerosis	0.00415	0.0423	CcSEcCtD
Tolmetin—Gastrointestinal haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.00402	0.0409	CcSEcCtD
Tolmetin—CXCL8—IL8- and CXCR1-mediated signaling events—RAB5A—amyotrophic lateral sclerosis	0.00401	0.0302	CbGpPWpGaD
Tolmetin—Gastritis—Riluzole—amyotrophic lateral sclerosis	0.00355	0.0362	CcSEcCtD
Tolmetin—CXCL8—IL8- and CXCR2-mediated signaling events—RAB5A—amyotrophic lateral sclerosis	0.00343	0.0259	CbGpPWpGaD
Tolmetin—CXCL8—Spinal Cord Injury—PTPRZ1—amyotrophic lateral sclerosis	0.00343	0.0259	CbGpPWpGaD
Tolmetin—Abdominal discomfort—Riluzole—amyotrophic lateral sclerosis	0.00333	0.0339	CcSEcCtD
Tolmetin—TDO2—Amino acid and derivative metabolism—DAO—amyotrophic lateral sclerosis	0.00332	0.0251	CbGpPWpGaD
Tolmetin—Dysuria—Riluzole—amyotrophic lateral sclerosis	0.00325	0.0331	CcSEcCtD
Tolmetin—Weight increased—Riluzole—amyotrophic lateral sclerosis	0.00316	0.0322	CcSEcCtD
Tolmetin—PTGS2—hindlimb—amyotrophic lateral sclerosis	0.00315	0.102	CbGeAlD
Tolmetin—Weight decreased—Riluzole—amyotrophic lateral sclerosis	0.00314	0.032	CcSEcCtD
Tolmetin—Stomatitis—Riluzole—amyotrophic lateral sclerosis	0.00302	0.0307	CcSEcCtD
Tolmetin—Urinary tract infection—Riluzole—amyotrophic lateral sclerosis	0.00301	0.0307	CcSEcCtD
Tolmetin—Haematuria—Riluzole—amyotrophic lateral sclerosis	0.00295	0.0301	CcSEcCtD
Tolmetin—TDO2—nervous system—amyotrophic lateral sclerosis	0.00295	0.0959	CbGeAlD
Tolmetin—Epistaxis—Riluzole—amyotrophic lateral sclerosis	0.00292	0.0298	CcSEcCtD
Tolmetin—Agranulocytosis—Riluzole—amyotrophic lateral sclerosis	0.00289	0.0294	CcSEcCtD
Tolmetin—TDO2—central nervous system—amyotrophic lateral sclerosis	0.00284	0.0923	CbGeAlD
Tolmetin—Hepatitis—Riluzole—amyotrophic lateral sclerosis	0.00278	0.0283	CcSEcCtD
Tolmetin—CXCL8—Unfolded Protein Response (UPR)—YIF1A—amyotrophic lateral sclerosis	0.00274	0.0207	CbGpPWpGaD
Tolmetin—PTGS2—appendage—amyotrophic lateral sclerosis	0.0027	0.0878	CbGeAlD
Tolmetin—Erythema multiforme—Riluzole—amyotrophic lateral sclerosis	0.00263	0.0268	CcSEcCtD
Tolmetin—Flatulence—Riluzole—amyotrophic lateral sclerosis	0.00238	0.0243	CcSEcCtD
Tolmetin—CXCL8—Unfolded Protein Response (UPR)—EXOSC9—amyotrophic lateral sclerosis	0.00226	0.017	CbGpPWpGaD
Tolmetin—TDO2—brain—amyotrophic lateral sclerosis	0.00225	0.0733	CbGeAlD
Tolmetin—MPO—Selenium Micronutrient Network—GSR—amyotrophic lateral sclerosis	0.00224	0.0169	CbGpPWpGaD
Tolmetin—CXCL8—medulla oblongata—amyotrophic lateral sclerosis	0.00216	0.0703	CbGeAlD
Tolmetin—Chest pain—Riluzole—amyotrophic lateral sclerosis	0.00206	0.021	CcSEcCtD
Tolmetin—CXCL8—Corticotropin-releasing hormone—CASP12—amyotrophic lateral sclerosis	0.00204	0.0154	CbGpPWpGaD
Tolmetin—CXCL8—Corticotropin-releasing hormone—ECE1—amyotrophic lateral sclerosis	0.00204	0.0154	CbGpPWpGaD
Tolmetin—Anaphylactic shock—Riluzole—amyotrophic lateral sclerosis	0.00197	0.0201	CcSEcCtD
Tolmetin—Oedema—Riluzole—amyotrophic lateral sclerosis	0.00197	0.0201	CcSEcCtD
Tolmetin—Thrombocytopenia—Riluzole—amyotrophic lateral sclerosis	0.00193	0.0197	CcSEcCtD
Tolmetin—CXCL8—spinal cord—amyotrophic lateral sclerosis	0.00193	0.0627	CbGeAlD
Tolmetin—Somnolence—Riluzole—amyotrophic lateral sclerosis	0.00176	0.0179	CcSEcCtD
Tolmetin—Dyspepsia—Riluzole—amyotrophic lateral sclerosis	0.00174	0.0177	CcSEcCtD
Tolmetin—Constipation—Riluzole—amyotrophic lateral sclerosis	0.00169	0.0172	CcSEcCtD
Tolmetin—CXCL8—Unfolded Protein Response (UPR)—DCTN1—amyotrophic lateral sclerosis	0.00162	0.0122	CbGpPWpGaD
Tolmetin—Gastrointestinal pain—Riluzole—amyotrophic lateral sclerosis	0.00161	0.0165	CcSEcCtD
Tolmetin—Urticaria—Riluzole—amyotrophic lateral sclerosis	0.00157	0.016	CcSEcCtD
Tolmetin—MPO—Vitamin B12 Metabolism—SOD1—amyotrophic lateral sclerosis	0.00157	0.0118	CbGpPWpGaD
Tolmetin—Body temperature increased—Riluzole—amyotrophic lateral sclerosis	0.00156	0.0159	CcSEcCtD
Tolmetin—Abdominal pain—Riluzole—amyotrophic lateral sclerosis	0.00156	0.0159	CcSEcCtD
Tolmetin—CXCL8—LPA receptor mediated events—MAPT—amyotrophic lateral sclerosis	0.00153	0.0115	CbGpPWpGaD
Tolmetin—CXCL8—cerebellum—amyotrophic lateral sclerosis	0.00153	0.0497	CbGeAlD
Tolmetin—Ketorolac—PTGS2—amyotrophic lateral sclerosis	0.00151	0.221	CrCbGaD
Tolmetin—PTGS2—Spinal Cord Injury—PTPRZ1—amyotrophic lateral sclerosis	0.0015	0.0113	CbGpPWpGaD
Tolmetin—PTGS2—Signaling mediated by p38-alpha and p38-beta—RAB5A—amyotrophic lateral sclerosis	0.00147	0.0111	CbGpPWpGaD
Tolmetin—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—TPK1—amyotrophic lateral sclerosis	0.00145	0.011	CbGpPWpGaD
Tolmetin—Bromfenac—PTGS2—amyotrophic lateral sclerosis	0.00144	0.212	CrCbGaD
Tolmetin—Asthenia—Riluzole—amyotrophic lateral sclerosis	0.00142	0.0144	CcSEcCtD
Tolmetin—Diarrhoea—Riluzole—amyotrophic lateral sclerosis	0.00135	0.0138	CcSEcCtD
Tolmetin—CXCL8—SIDS Susceptibility Pathways—ECE1—amyotrophic lateral sclerosis	0.00134	0.0101	CbGpPWpGaD
Tolmetin—CXCL8—Spinal Cord Injury—RTN4—amyotrophic lateral sclerosis	0.00134	0.0101	CbGpPWpGaD
Tolmetin—Dizziness—Riluzole—amyotrophic lateral sclerosis	0.00131	0.0133	CcSEcCtD
Tolmetin—CXCL8—Overview of nanoparticle effects—PTGS2—amyotrophic lateral sclerosis	0.00129	0.00977	CbGpPWpGaD
Tolmetin—MPO—Folate Metabolism—SOD1—amyotrophic lateral sclerosis	0.00128	0.00962	CbGpPWpGaD
Tolmetin—Vomiting—Riluzole—amyotrophic lateral sclerosis	0.00126	0.0128	CcSEcCtD
Tolmetin—CXCL8—brain—amyotrophic lateral sclerosis	0.00124	0.0404	CbGeAlD
Tolmetin—Headache—Riluzole—amyotrophic lateral sclerosis	0.00124	0.0126	CcSEcCtD
Tolmetin—Lumiracoxib—PTGS2—amyotrophic lateral sclerosis	0.00123	0.18	CrCbGaD
Tolmetin—Nausea—Riluzole—amyotrophic lateral sclerosis	0.00117	0.0119	CcSEcCtD
Tolmetin—MPO—Vitamin B12 Metabolism—APOE—amyotrophic lateral sclerosis	0.00116	0.00872	CbGpPWpGaD
Tolmetin—MPO—spinal cord—amyotrophic lateral sclerosis	0.00113	0.0366	CbGeAlD
Tolmetin—Fenbufen—PTGS2—amyotrophic lateral sclerosis	0.00112	0.164	CrCbGaD
Tolmetin—CXCL8—Spinal Cord Injury—GFAP—amyotrophic lateral sclerosis	0.00109	0.00823	CbGpPWpGaD
Tolmetin—CXCL8—Spinal Cord Injury—AQP4—amyotrophic lateral sclerosis	0.00108	0.00814	CbGpPWpGaD
Tolmetin—CXCL8—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CD40LG—amyotrophic lateral sclerosis	0.00106	0.00799	CbGpPWpGaD
Tolmetin—MPO—Selenium Micronutrient Network—SOD1—amyotrophic lateral sclerosis	0.00101	0.00764	CbGpPWpGaD
Tolmetin—SLC22A6—brain—amyotrophic lateral sclerosis	0.000969	0.0315	CbGeAlD
Tolmetin—MPO—nervous system—amyotrophic lateral sclerosis	0.000949	0.0309	CbGeAlD
Tolmetin—CXCL8—Senescence and Autophagy in Cancer—IGFBP3—amyotrophic lateral sclerosis	0.000941	0.0071	CbGpPWpGaD
Tolmetin—Suprofen—PTGS2—amyotrophic lateral sclerosis	0.000931	0.137	CrCbGaD
Tolmetin—PTGS1—Selenium Micronutrient Network—GSR—amyotrophic lateral sclerosis	0.000917	0.00691	CbGpPWpGaD
Tolmetin—MPO—central nervous system—amyotrophic lateral sclerosis	0.000914	0.0297	CbGeAlD
Tolmetin—CXCL8—Allograft Rejection—CASP9—amyotrophic lateral sclerosis	0.000913	0.00688	CbGpPWpGaD
Tolmetin—PTGS1—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—PTGS2—amyotrophic lateral sclerosis	0.000912	0.00688	CbGpPWpGaD
Tolmetin—PTGS2—embryo—amyotrophic lateral sclerosis	0.000897	0.0292	CbGeAlD
Tolmetin—PTGS1—Prostaglandin Synthesis and Regulation—PLA2G4A—amyotrophic lateral sclerosis	0.000879	0.00663	CbGpPWpGaD
Tolmetin—CXCL8—SIDS Susceptibility Pathways—SLC1A3—amyotrophic lateral sclerosis	0.000863	0.00651	CbGpPWpGaD
Tolmetin—CXCL8—SIDS Susceptibility Pathways—CHAT—amyotrophic lateral sclerosis	0.000863	0.00651	CbGpPWpGaD
Tolmetin—CXCL8—SIDS Susceptibility Pathways—AQP4—amyotrophic lateral sclerosis	0.000863	0.00651	CbGpPWpGaD
Tolmetin—TDO2—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000844	0.00636	CbGpPWpGaD
Tolmetin—TDO2—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000844	0.00636	CbGpPWpGaD
Tolmetin—CXCL8—Metabolism of proteins—IGFALS—amyotrophic lateral sclerosis	0.000841	0.00635	CbGpPWpGaD
Tolmetin—CXCL8—Senescence and Autophagy in Cancer—SQSTM1—amyotrophic lateral sclerosis	0.000814	0.00614	CbGpPWpGaD
Tolmetin—CXCL8—Corticotropin-releasing hormone—CASP9—amyotrophic lateral sclerosis	0.000808	0.00609	CbGpPWpGaD
Tolmetin—PTGS2—Signaling mediated by p38-alpha and p38-beta—ATF1—amyotrophic lateral sclerosis	0.000805	0.00607	CbGpPWpGaD
Tolmetin—TDO2—Metabolism—VAPA—amyotrophic lateral sclerosis	0.000772	0.00582	CbGpPWpGaD
Tolmetin—SLC22A6—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A1—amyotrophic lateral sclerosis	0.000767	0.00578	CbGpPWpGaD
Tolmetin—CXCL8—Peptide ligand-binding receptors—C5AR1—amyotrophic lateral sclerosis	0.000737	0.00556	CbGpPWpGaD
Tolmetin—CXCL8—Allograft Rejection—CD40LG—amyotrophic lateral sclerosis	0.000735	0.00554	CbGpPWpGaD
Tolmetin—PTGS2—Selenium Micronutrient Network—GSR—amyotrophic lateral sclerosis	0.000728	0.00549	CbGpPWpGaD
Tolmetin—MPO—brain—amyotrophic lateral sclerosis	0.000726	0.0236	CbGeAlD
Tolmetin—CXCL8—Syndecan-2-mediated signaling events—CASP3—amyotrophic lateral sclerosis	0.000721	0.00544	CbGpPWpGaD
Tolmetin—TDO2—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.000717	0.00541	CbGpPWpGaD
Tolmetin—PTGS2—Calcium signaling in the CD4+ TCR pathway—CD40LG—amyotrophic lateral sclerosis	0.000717	0.00541	CbGpPWpGaD
Tolmetin—PTGS1—Overview of nanoparticle effects—PTGS2—amyotrophic lateral sclerosis	0.000714	0.00539	CbGpPWpGaD
Tolmetin—PTGS2—Prostaglandin Synthesis and Regulation—PLA2G4A—amyotrophic lateral sclerosis	0.000698	0.00527	CbGpPWpGaD
Tolmetin—CXCL8—Cellular responses to stress—GSR—amyotrophic lateral sclerosis	0.00069	0.0052	CbGpPWpGaD
Tolmetin—CXCL8—Bladder Cancer—VEGFA—amyotrophic lateral sclerosis	0.000689	0.0052	CbGpPWpGaD
Tolmetin—TDO2—Metabolism—FIG4—amyotrophic lateral sclerosis	0.000674	0.00509	CbGpPWpGaD
Tolmetin—CXCL8—Validated transcriptional targets of AP1 family members Fra1 and Fra2—MMP9—amyotrophic lateral sclerosis	0.000666	0.00503	CbGpPWpGaD
Tolmetin—CXCL8—Cellular responses to stress—VCP—amyotrophic lateral sclerosis	0.000666	0.00503	CbGpPWpGaD
Tolmetin—CXCL8—Regulation of toll-like receptor signaling pathway—SQSTM1—amyotrophic lateral sclerosis	0.00065	0.0049	CbGpPWpGaD
Tolmetin—CXCL8—Allograft Rejection—C3—amyotrophic lateral sclerosis	0.000649	0.0049	CbGpPWpGaD
Tolmetin—CXCL8—Metabolism of proteins—PIGW—amyotrophic lateral sclerosis	0.000638	0.00481	CbGpPWpGaD
Tolmetin—CXCL8—G alpha (i) signalling events—C5AR1—amyotrophic lateral sclerosis	0.000622	0.00469	CbGpPWpGaD
Tolmetin—PTGS2—Signaling mediated by p38-alpha and p38-beta—PLA2G4A—amyotrophic lateral sclerosis	0.000617	0.00465	CbGpPWpGaD
Tolmetin—TDO2—Metabolism—DAO—amyotrophic lateral sclerosis	0.00061	0.0046	CbGpPWpGaD
Tolmetin—CXCL8—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—PTGS2—amyotrophic lateral sclerosis	0.000597	0.0045	CbGpPWpGaD
Tolmetin—PTGS1—Eicosanoid Synthesis—PTGS2—amyotrophic lateral sclerosis	0.000593	0.00447	CbGpPWpGaD
Tolmetin—Indomethacin—PTGS2—amyotrophic lateral sclerosis	0.000592	0.0868	CrCbGaD
Tolmetin—PTGS2—Spinal Cord Injury—RTN4—amyotrophic lateral sclerosis	0.000586	0.00442	CbGpPWpGaD
Tolmetin—PTGS1—Arachidonic acid metabolism—PLA2G4A—amyotrophic lateral sclerosis	0.000584	0.00441	CbGpPWpGaD
Tolmetin—CXCL8—Metabolism of proteins—XRN2—amyotrophic lateral sclerosis	0.000583	0.0044	CbGpPWpGaD
Tolmetin—PTGS2—medulla oblongata—amyotrophic lateral sclerosis	0.000573	0.0186	CbGeAlD
Tolmetin—CXCL8—Spinal Cord Injury—BDNF—amyotrophic lateral sclerosis	0.000558	0.00421	CbGpPWpGaD
Tolmetin—CXCL8—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CASP3—amyotrophic lateral sclerosis	0.000554	0.00418	CbGpPWpGaD
Tolmetin—PTGS1—spinal cord—amyotrophic lateral sclerosis	0.000535	0.0174	CbGeAlD
Tolmetin—MPO—C-MYB transcription factor network—PTGS2—amyotrophic lateral sclerosis	0.000532	0.00401	CbGpPWpGaD
Tolmetin—CXCL8—Bladder Cancer—TP53—amyotrophic lateral sclerosis	0.000521	0.00393	CbGpPWpGaD
Tolmetin—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—amyotrophic lateral sclerosis	0.000513	0.00387	CbGpPWpGaD
Tolmetin—MPO—Selenium Micronutrient Network—PTGS2—amyotrophic lateral sclerosis	0.000512	0.00386	CbGpPWpGaD
Tolmetin—PTGS2—spinal cord—amyotrophic lateral sclerosis	0.000511	0.0166	CbGeAlD
Tolmetin—PTGS2—Integrated Pancreatic Cancer Pathway—CASP12—amyotrophic lateral sclerosis	0.000499	0.00376	CbGpPWpGaD
Tolmetin—PTGS1—Prostaglandin Synthesis and Regulation—PTGS2—amyotrophic lateral sclerosis	0.000496	0.00374	CbGpPWpGaD
Tolmetin—CXCL8—Class A/1 (Rhodopsin-like receptors)—C5AR1—amyotrophic lateral sclerosis	0.000494	0.00373	CbGpPWpGaD
Tolmetin—CXCL8—Metabolism of proteins—YIF1A—amyotrophic lateral sclerosis	0.000483	0.00365	CbGpPWpGaD
Tolmetin—PTGS2—Spinal Cord Injury—GFAP—amyotrophic lateral sclerosis	0.000478	0.00361	CbGpPWpGaD
Tolmetin—PTGS2—Spinal Cord Injury—AQP4—amyotrophic lateral sclerosis	0.000473	0.00356	CbGpPWpGaD
Tolmetin—PTGS2—Arachidonic acid metabolism—PLA2G4A—amyotrophic lateral sclerosis	0.000464	0.0035	CbGpPWpGaD
Tolmetin—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CD40LG—amyotrophic lateral sclerosis	0.000464	0.0035	CbGpPWpGaD
Tolmetin—TDO2—Metabolism—PLB1—amyotrophic lateral sclerosis	0.000462	0.00349	CbGpPWpGaD
Tolmetin—SLC22A6—SLC-mediated transmembrane transport—SLC1A2—amyotrophic lateral sclerosis	0.00046	0.00347	CbGpPWpGaD
Tolmetin—CXCL8—LPA receptor mediated events—CASP3—amyotrophic lateral sclerosis	0.000455	0.00343	CbGpPWpGaD
Tolmetin—PTGS1—nervous system—amyotrophic lateral sclerosis	0.00045	0.0146	CbGeAlD
Tolmetin—PTGS2—S1P1 pathway—VEGFA—amyotrophic lateral sclerosis	0.000447	0.00337	CbGpPWpGaD
Tolmetin—CXCL8—SIDS Susceptibility Pathways—BDNF—amyotrophic lateral sclerosis	0.000446	0.00337	CbGpPWpGaD
Tolmetin—PTGS1—central nervous system—amyotrophic lateral sclerosis	0.000434	0.0141	CbGeAlD
Tolmetin—PTGS2—nervous system—amyotrophic lateral sclerosis	0.000431	0.014	CbGeAlD
Tolmetin—CXCL8—LPA receptor mediated events—MMP9—amyotrophic lateral sclerosis	0.00043	0.00324	CbGpPWpGaD
Tolmetin—TDO2—Metabolism—GSR—amyotrophic lateral sclerosis	0.000427	0.00322	CbGpPWpGaD
Tolmetin—PTGS1—Selenium Micronutrient Network—SOD1—amyotrophic lateral sclerosis	0.000415	0.00313	CbGpPWpGaD
Tolmetin—PTGS2—central nervous system—amyotrophic lateral sclerosis	0.000414	0.0135	CbGeAlD
Tolmetin—PTGS1—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	0.000407	0.00307	CbGpPWpGaD
Tolmetin—PTGS2—Integrated Pancreatic Cancer Pathway—RARA—amyotrophic lateral sclerosis	0.000407	0.00307	CbGpPWpGaD
Tolmetin—PTGS2—cerebellum—amyotrophic lateral sclerosis	0.000405	0.0132	CbGeAlD
Tolmetin—CXCL8—AP-1 transcription factor network—MMP9—amyotrophic lateral sclerosis	0.0004	0.00302	CbGpPWpGaD
Tolmetin—CXCL8—Metabolism of proteins—EXOSC9—amyotrophic lateral sclerosis	0.000398	0.003	CbGpPWpGaD
Tolmetin—CXCL8—Senescence and Autophagy in Cancer—IGF1—amyotrophic lateral sclerosis	0.000398	0.003	CbGpPWpGaD
Tolmetin—SLC22A6—SLC-mediated transmembrane transport—SLC1A3—amyotrophic lateral sclerosis	0.000391	0.00295	CbGpPWpGaD
Tolmetin—CXCL8—Allograft Rejection—CASP3—amyotrophic lateral sclerosis	0.000384	0.0029	CbGpPWpGaD
Tolmetin—MPO—Folate Metabolism—TP53—amyotrophic lateral sclerosis	0.000384	0.00289	CbGpPWpGaD
Tolmetin—CXCL8—GPCR ligand binding—C5AR1—amyotrophic lateral sclerosis	0.000376	0.00284	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	0.000372	0.00281	CbGpPWpGaD
Tolmetin—SLC22A6—Transmembrane transport of small molecules—TRPM7—amyotrophic lateral sclerosis	0.000363	0.00274	CbGpPWpGaD
Tolmetin—CXCL8—Regulation of nuclear beta catenin signaling and target gene transcription—MMP9—amyotrophic lateral sclerosis	0.00036	0.00271	CbGpPWpGaD
Tolmetin—TDO2—Metabolism—CHAT—amyotrophic lateral sclerosis	0.00035	0.00264	CbGpPWpGaD
Tolmetin—SLC22A6—SLC-mediated transmembrane transport—SLC6A1—amyotrophic lateral sclerosis	0.000348	0.00263	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	0.000346	0.00261	CbGpPWpGaD
Tolmetin—PTGS1—brain—amyotrophic lateral sclerosis	0.000344	0.0112	CbGeAlD
Tolmetin—CXCL8—Corticotropin-releasing hormone—CASP3—amyotrophic lateral sclerosis	0.00034	0.00257	CbGpPWpGaD
Tolmetin—CXCL8—Metabolism of proteins—TUBA4A—amyotrophic lateral sclerosis	0.000335	0.00253	CbGpPWpGaD
Tolmetin—PTGS1—Arachidonic acid metabolism—PTGS2—amyotrophic lateral sclerosis	0.000329	0.00249	CbGpPWpGaD
Tolmetin—PTGS2—Selenium Micronutrient Network—SOD1—amyotrophic lateral sclerosis	0.000329	0.00248	CbGpPWpGaD
Tolmetin—PTGS2—brain—amyotrophic lateral sclerosis	0.000329	0.0107	CbGeAlD
Tolmetin—CXCL8—Allograft Rejection—VEGFA—amyotrophic lateral sclerosis	0.000326	0.00246	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	0.000326	0.00246	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	0.000323	0.00244	CbGpPWpGaD
Tolmetin—CXCL8—Peptide ligand-binding receptors—C3—amyotrophic lateral sclerosis	0.000322	0.00243	CbGpPWpGaD
Tolmetin—CXCL8—Cellular responses to stress—SOD1—amyotrophic lateral sclerosis	0.000312	0.00235	CbGpPWpGaD
Tolmetin—CXCL8—Cellular responses to stress—GSTP1—amyotrophic lateral sclerosis	0.000304	0.0023	CbGpPWpGaD
Tolmetin—CXCL8—Spinal Cord Injury—PTGS2—amyotrophic lateral sclerosis	0.0003	0.00227	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	0.000296	0.00223	CbGpPWpGaD
Tolmetin—CXCL8—Metabolism of proteins—DCTN1—amyotrophic lateral sclerosis	0.000285	0.00215	CbGpPWpGaD
Tolmetin—PTGS2—Integrated Pancreatic Cancer Pathway—MAPT—amyotrophic lateral sclerosis	0.00028	0.00211	CbGpPWpGaD
Tolmetin—CXCL8—Spinal Cord Injury—CASP3—amyotrophic lateral sclerosis	0.000279	0.0021	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	0.000275	0.00207	CbGpPWpGaD
Tolmetin—CXCL8—AP-1 transcription factor network—TP53—amyotrophic lateral sclerosis	0.000272	0.00205	CbGpPWpGaD
Tolmetin—CXCL8—G alpha (i) signalling events—C3—amyotrophic lateral sclerosis	0.000271	0.00205	CbGpPWpGaD
Tolmetin—PTGS2—Integrated Pancreatic Cancer Pathway—CST3—amyotrophic lateral sclerosis	0.000271	0.00205	CbGpPWpGaD
Tolmetin—CXCL8—Spinal Cord Injury—MMP9—amyotrophic lateral sclerosis	0.000264	0.00199	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	0.000258	0.00195	CbGpPWpGaD
Tolmetin—PTGS2—Integrated Pancreatic Cancer Pathway—IGFBP3—amyotrophic lateral sclerosis	0.000255	0.00193	CbGpPWpGaD
Tolmetin—PTGS2—Spinal Cord Injury—BDNF—amyotrophic lateral sclerosis	0.000245	0.00184	CbGpPWpGaD
Tolmetin—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CASP3—amyotrophic lateral sclerosis	0.000243	0.00183	CbGpPWpGaD
Tolmetin—CXCL8—Glucocorticoid receptor regulatory network—TP53—amyotrophic lateral sclerosis	0.000239	0.0018	CbGpPWpGaD
Tolmetin—PTGS1—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	0.000237	0.00179	CbGpPWpGaD
Tolmetin—SLC22A6—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	0.000234	0.00176	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	0.000223	0.00168	CbGpPWpGaD
Tolmetin—CXCL8—SIDS Susceptibility Pathways—CASP3—amyotrophic lateral sclerosis	0.000223	0.00168	CbGpPWpGaD
Tolmetin—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—amyotrophic lateral sclerosis	0.00022	0.00166	CbGpPWpGaD
Tolmetin—CXCL8—Class A/1 (Rhodopsin-like receptors)—C3—amyotrophic lateral sclerosis	0.000216	0.00163	CbGpPWpGaD
Tolmetin—CXCL8—GPCR downstream signaling—C5AR1—amyotrophic lateral sclerosis	0.000213	0.0016	CbGpPWpGaD
Tolmetin—CXCL8—Metabolism of proteins—IGFBP3—amyotrophic lateral sclerosis	0.00021	0.00159	CbGpPWpGaD
Tolmetin—PTGS1—Selenium Micronutrient Network—PTGS2—amyotrophic lateral sclerosis	0.00021	0.00158	CbGpPWpGaD
Tolmetin—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—amyotrophic lateral sclerosis	0.000207	0.00156	CbGpPWpGaD
Tolmetin—SLC22A6—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	0.000199	0.0015	CbGpPWpGaD
Tolmetin—SLC22A6—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	0.000199	0.0015	CbGpPWpGaD
Tolmetin—PTGS2—Integrated Pancreatic Cancer Pathway—CASP9—amyotrophic lateral sclerosis	0.000197	0.00149	CbGpPWpGaD
Tolmetin—CXCL8—Senescence and Autophagy in Cancer—TP53—amyotrophic lateral sclerosis	0.000196	0.00148	CbGpPWpGaD
Tolmetin—CXCL8—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	0.000193	0.00146	CbGpPWpGaD
Tolmetin—CXCL8—SIDS Susceptibility Pathways—VEGFA—amyotrophic lateral sclerosis	0.000189	0.00143	CbGpPWpGaD
Tolmetin—TDO2—Metabolism—GSTP1—amyotrophic lateral sclerosis	0.000188	0.00142	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000181	0.00137	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000181	0.00137	CbGpPWpGaD
Tolmetin—CXCL8—Spinal Cord Injury—TP53—amyotrophic lateral sclerosis	0.000179	0.00135	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	0.000177	0.00134	CbGpPWpGaD
Tolmetin—SLC22A6—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	0.000177	0.00134	CbGpPWpGaD
Tolmetin—TDO2—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	0.000173	0.00131	CbGpPWpGaD
Tolmetin—PTGS2—Disease—TPK1—amyotrophic lateral sclerosis	0.000172	0.0013	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	0.000169	0.00128	CbGpPWpGaD
Tolmetin—PTGS2—Integrated Pancreatic Cancer Pathway—BDNF—amyotrophic lateral sclerosis	0.000166	0.00125	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—VAPA—amyotrophic lateral sclerosis	0.000166	0.00125	CbGpPWpGaD
Tolmetin—CXCL8—GPCR ligand binding—C3—amyotrophic lateral sclerosis	0.000164	0.00124	CbGpPWpGaD
Tolmetin—PTGS2—Integrated Pancreatic Cancer Pathway—PLA2G4A—amyotrophic lateral sclerosis	0.000159	0.0012	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.000154	0.00116	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	0.000151	0.00114	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—FIG4—amyotrophic lateral sclerosis	0.000145	0.00109	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000144	0.00109	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000144	0.00109	CbGpPWpGaD
Tolmetin—TDO2—Metabolism—APOE—amyotrophic lateral sclerosis	0.000142	0.00107	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	0.000142	0.00107	CbGpPWpGaD
Tolmetin—PTGS2—Disease—VTA1—amyotrophic lateral sclerosis	0.000137	0.00104	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	0.000134	0.00101	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—VCP—amyotrophic lateral sclerosis	0.000134	0.00101	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—VAPA—amyotrophic lateral sclerosis	0.000132	0.000993	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—DAO—amyotrophic lateral sclerosis	0.000131	0.000989	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	0.00013	0.00098	CbGpPWpGaD
Tolmetin—CXCL8—Cellular responses to stress—VEGFA—amyotrophic lateral sclerosis	0.000124	0.000937	CbGpPWpGaD
Tolmetin—CXCL8—Cellular Senescence—TP53—amyotrophic lateral sclerosis	0.000124	0.000937	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.000122	0.000923	CbGpPWpGaD
Tolmetin—PTGS2—Spinal Cord Injury—CASP3—amyotrophic lateral sclerosis	0.000122	0.000921	CbGpPWpGaD
Tolmetin—PTGS2—Spinal Cord Injury—MMP9—amyotrophic lateral sclerosis	0.000115	0.000871	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	0.000115	0.000871	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—FIG4—amyotrophic lateral sclerosis	0.000115	0.000868	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	0.000114	0.000861	CbGpPWpGaD
Tolmetin—PTGS2—Integrated Pancreatic Cancer Pathway—IGF1—amyotrophic lateral sclerosis	0.000108	0.000814	CbGpPWpGaD
Tolmetin—PTGS2—Disease—CHMP2B—amyotrophic lateral sclerosis	0.000104	0.000786	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—DAO—amyotrophic lateral sclerosis	0.000104	0.000785	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—PLB1—amyotrophic lateral sclerosis	9.94e-05	0.00075	CbGpPWpGaD
Tolmetin—TDO2—Metabolism—PTGS2—amyotrophic lateral sclerosis	9.75e-05	0.000736	CbGpPWpGaD
Tolmetin—CXCL8—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	9.54e-05	0.00072	CbGpPWpGaD
Tolmetin—PTGS2—Disease—PLB1—amyotrophic lateral sclerosis	9.42e-05	0.000711	CbGpPWpGaD
Tolmetin—CXCL8—Cellular responses to stress—TP53—amyotrophic lateral sclerosis	9.39e-05	0.000708	CbGpPWpGaD
Tolmetin—CXCL8—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	9.29e-05	0.0007	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—GSR—amyotrophic lateral sclerosis	9.17e-05	0.000692	CbGpPWpGaD
Tolmetin—CXCL8—Metabolism of proteins—IGF1—amyotrophic lateral sclerosis	8.89e-05	0.000671	CbGpPWpGaD
Tolmetin—CXCL8—Signaling by GPCR—C3—amyotrophic lateral sclerosis	8.43e-05	0.000636	CbGpPWpGaD
Tolmetin—PTGS2—Disease—VCP—amyotrophic lateral sclerosis	8.4e-05	0.000633	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	8.35e-05	0.00063	CbGpPWpGaD
Tolmetin—PTGS2—Integrated Pancreatic Cancer Pathway—CASP3—amyotrophic lateral sclerosis	8.31e-05	0.000627	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—PLB1—amyotrophic lateral sclerosis	7.89e-05	0.000595	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	7.84e-05	0.000591	CbGpPWpGaD
Tolmetin—PTGS2—Spinal Cord Injury—TP53—amyotrophic lateral sclerosis	7.83e-05	0.000591	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—CHAT—amyotrophic lateral sclerosis	7.53e-05	0.000568	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	7.35e-05	0.000555	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—GSR—amyotrophic lateral sclerosis	7.28e-05	0.000549	CbGpPWpGaD
Tolmetin—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	7.05e-05	0.000532	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	7e-05	0.000528	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	6.87e-05	0.000518	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	6.63e-05	0.0005	CbGpPWpGaD
Tolmetin—PTGS2—Disease—CST3—amyotrophic lateral sclerosis	6.03e-05	0.000455	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	6e-05	0.000452	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—CHAT—amyotrophic lateral sclerosis	5.98e-05	0.000451	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	5.64e-05	0.000425	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	5.46e-05	0.000411	CbGpPWpGaD
Tolmetin—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	5.33e-05	0.000402	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—C3—amyotrophic lateral sclerosis	4.98e-05	0.000376	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	4.71e-05	0.000355	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—APOE—amyotrophic lateral sclerosis	4.64e-05	0.00035	CbGpPWpGaD
Tolmetin—PTGS2—Disease—CASP9—amyotrophic lateral sclerosis	4.38e-05	0.00033	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—GSTP1—amyotrophic lateral sclerosis	4.05e-05	0.000305	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	3.83e-05	0.000289	CbGpPWpGaD
Tolmetin—PTGS2—Disease—ERBB4—amyotrophic lateral sclerosis	3.75e-05	0.000283	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	3.72e-05	0.000281	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—GSTP1—amyotrophic lateral sclerosis	3.21e-05	0.000242	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—APOE—amyotrophic lateral sclerosis	3.06e-05	0.000231	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	2.95e-05	0.000223	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	2.95e-05	0.000222	CbGpPWpGaD
Tolmetin—PTGS2—Disease—APOE—amyotrophic lateral sclerosis	2.9e-05	0.000219	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	2.79e-05	0.00021	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	2.5e-05	0.000189	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—APOE—amyotrophic lateral sclerosis	2.43e-05	0.000183	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—PTGS2—amyotrophic lateral sclerosis	2.1e-05	0.000158	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—TP53—amyotrophic lateral sclerosis	1.89e-05	0.000143	CbGpPWpGaD
